Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids Source: Eur Respir J 2001; 17: 337-342 Year: 2001
Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005
Where current pharmacological therapies fall short in COPD: symptom control is not enough Source: Eur Respir Rev 2007; 16: 98-104 Year: 2007
Increased oxidative stress in patients with chronic obstructive pulmonary disease (COPD) and metabolic syndrome (MetS) Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench Year: 2013
Impact of oxygen supplementation on inflammatory response and muscle lesion during high intensity exercise on chronic obstructive pulmonary disease (COPD) patients Source: Annual Congress 2006 - Muscles, training and rehabilitation Year: 2006
Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
A comparison of the effects of lung function between low dose theophylline and oral β2-agonist in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 215s Year: 2006
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001
Formoterol demonstrates bronchodilator efficacy in patients with reversible or poorly reversible chronic obstructive pulmonary disease (COPD), regardless of concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 177s Year: 2001
Subphenotyping COPD: is it relevant for therapeutic intervention and disease outcome? Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005
Systemic effects of chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=224 Year: 2006
Serum and skeletal muscle leptin in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2005 - Systemic effects of COPD Year: 2005
Comparison of blood eosinophils and plasma periostin in stable and non-stable chronic obstructive pulmonary disease: How we can improve the management of our patients Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016
Association between serum leptin, nutritional status and severity of chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - COPD: from bench to bedside Year: 2008
Effects of an acute exacerbation requiring hospitalisation (AE) on lung function, muscle force and serum IGF-I levels in male patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 564s Year: 2002
The positive effect of cilomilast on lung function in patients with chronic obstructive pulmonary disease (COPD) is independent of patient smoking status Source: Eur Respir J 2002; 20: Suppl. 38, 620s Year: 2002
Systemic inflammation and increased arterial stiffness in patients with chronic obstructive pulmonary disease Source: Annual Congress 2006 - COPD and inflammation Year: 2006
Simvastatin does not reduce levels of inflammatory blood markers in patients with stable chronic obstructive pulmonary disease Source: Annual Congress 2008 - COPD Year: 2008
Influence of systemic inflammation and hypoxaemia on bone metabolism in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –COPD diagnosis Year: 2013
Baseline data and responses to oral steroid intervention in asthma and COPD: interim report from the BIOAIR EU study Source: Annual Congress 2007 - Asthma subphenotypes Year: 2007